Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 11/13/2025 at 06:35, 21 days 23 hours ago

Formycon AG Confirms 2025 Guidance Amid Pipeline and Partnership Progress

Financial Results Strategic Partnerships Formycon AG Biosimilars Market Expansion
PRESS RELEASE

published on 11/13/2025 at 06:30, 21 days 23 hours ago

Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Formycon AG publishes nine-month results, reaffirms 2025 guidance with strong pipeline progress and partnerships. Read about fiscal performance and strategic advancements

Formycon AG Partnerships Pipeline Progress Nine-month Results 2025 Guidance
BRIEF

published on 10/30/2025 at 06:35, 1 month 5 days ago

Formycon AG Schedules Conference Call for 2025 Results and Investor Engagement

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
PRESS RELEASE

published on 10/30/2025 at 06:30, 1 month 5 days ago

Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Formycon AG to discuss 2025 Nine-Month Results in Conference Call and participate in Investor Conferences. Company specializes in biosimilars for various disease areas

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
BRIEF

published on 10/21/2025 at 06:35, 1 month 14 days ago

Formycon Launches Europe’s First Ranibizumab Biosimilar in Pre-filled Syringe

Teva Pharmaceuticals Ranibizumab Biosimilar Pre-filled Syringe FYB201/Ranivisio® Formycon Launch
PRESS RELEASE

published on 10/21/2025 at 06:30, 1 month 14 days ago

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe

Europe Biosimilar Formycon Teva Ranivisio
BRIEF

published on 10/16/2025 at 06:35, 1 month 19 days ago

Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG Eylea® Biosimilar Actor Pharmaceuticals Megalabs FYB203 Commercialization
PRESS RELEASE

published on 10/16/2025 at 06:30, 1 month 19 days ago

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties

Partnerships Commercialization Biosimilar Formycon Eylea
BRIEF

published on 10/02/2025 at 06:35, 2 months 2 days ago

Formycon Secures U.S. License for Aflibercept Biosimilar

Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
PRESS RELEASE

published on 10/02/2025 at 06:30, 2 months 2 days ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 41 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 46 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 16 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 11 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 16 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 45 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 25 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 50 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 5 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 16 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 31 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 31 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 15 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE